title: Saving orphans: BRAF targeting of histiocytosis.
abstract: In this issue of Blood, Haroche and colleagues report significant therapeutic activity of the BRAF inhibitor, vemurafenib, in 3 patients with rare histiocytic conditions, Erdheim-Chester disease and Langerhans cell histiocytosis.
authors: Columbia University Medical Center.
authors: Mark L
authors: ML
authors: Heaney
mesh_terms: D031249:Erdheim-Chester Disease / Q000188:drug therapy*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf